Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 12/20 | 0.38 |
| ▸ | HTR1A | P08908 | 9/20 | 0.38 |
| ▸ | DRD2 | P14416 | 7/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.38 |
| ▸ | HTR7 | P34969 | 3/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5420700 | 0.97 | ADRA1B (0.41) | HTR2AHTR1ADRD2ADRA1BADRA1D | |
| SCHEMBL5412405 | 0.95 | ACHE (0.36) | HTR2AHTR1ADRD2ADRA1BADRA1D | |
| SCHEMBL5423676 | 0.94 | HTR2A (0.41) | HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL5415015 | 0.92 | HTR2A (0.37) | HTR2AHTR1ADRD2ADRA1BADRA1D | |
| SCHEMBL5408232 | 0.88 | HTR2A (0.39) | HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL5414854 | 0.86 | ACHE (0.40) | HTR2AHTR1ADRD2ADRA1BADRA1D | |
| SCHEMBL5417889 | 0.84 | ADRA1B (0.40) | HTR2AHTR1ADRD2ADRA1BADRA1D | |
| SCHEMBL5423943 | 0.83 | NOS3 (0.41) | DRD2SMN1; SMN2 | |
| SCHEMBL5421510 | 0.83 | NOS3 (0.35) | DRD2 | |
| SCHEMBL5412606 | 0.82 | ADRA1B (0.40) | HTR2AHTR1ADRD2ADRA1BADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7160894-B2 | Antagonist of phosphorylation of myosin regulatory light chain, enzyme inhibitors; therapeutic treatment of glaucoma, bronchial asthma, chronic obstructive pulmonary disease, nervous system disorders; 4-(2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexylamine | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-01-09 | — | — | US | disclosed |
| EP-1632492-A1 | TRICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2006-03-08 | — | — | EP | disclosed |
| US-20050096310-A1 | Tricyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096310-A1 | Tricyclic compound | MYLK3, CSNK1A1L, MYLK | HTR2A 1671/4885HTR1A 443/4885DRD2 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.